Soreide Law Group is examining potential investor claims involving recommendations of NexPoint Capital Inc. BDC, a publicly registered non-traded business development company sponsored by NexPoint Advisors L.P., following continued declines in the investment’s net asset value (“NAV”), limited liquidity opportunities, and ongoing concerns about investor losses.
NexPoint Capital Inc. BDC was marketed as an income-focused alternative investment with significant exposure to healthcare-related assets, including senior housing and medical facilities. Investors should be aware of recent developments involving falling share values, continued distributions despite declining NAV, and concerns surrounding the risks of non-traded BDC investments. The information below summarizes important facts investors should know.
NexPoint Capital Inc. BDC is a non-traded business development company that invests primarily in private debt and alternative investments with a concentration in healthcare-related sectors. The investment has focused on senior housing, long-term care properties, and medical facilities intended to benefit from demographic trends tied to an aging population. Because the BDC is non-traded, investors generally do not have access to a public exchange to readily sell shares. The company also offers a dividend reinvestment plan (“DRIP”), which permits shareholders to reinvest distributions into additional shares priced in relation to the company’s NAV.
Recent reports show that NexPoint Capital Inc. BDC’s NAV declined from $4.60 per share at year-end 2025 to $4.30 per share as of March 31, 2026. Earlier reports also reflected a longer-term decline from approximately $6.13 per share in 2020. At the same time, the company maintained a $0.09 per share distribution payable in April 2026 despite continued decreases in NAV. Reports noted concerns that ongoing distributions during periods of declining NAV may, in some cases, involve a return of investor capital rather than investment income.
The company also launched a tender offer in February 2026 to repurchase only up to 1% of outstanding shares at approximately $4.43 per share, leaving many investors with limited liquidity options. Additional concerns include concentration in healthcare-related investments, sector-specific risks, valuation uncertainty, and the illiquid nature of non-traded BDCs. Reports further stated that DRIP shares are currently being issued at the declining $4.30 NAV price.
Brokers and financial advisors recommending NexPoint Capital Inc. BDC may have had obligations to fully explain the risks associated with declining NAV, limited liquidity, healthcare-sector concentration, and the speculative nature of non-traded BDCs.
Potential investor claims could involve recommendations that were unsuitable for conservative or income-oriented investors, failure to disclose that shares purchased at substantially higher prices had materially declined in value, misrepresentations regarding income stability or liquidity, overconcentration in illiquid alternative investments, or inadequate due diligence concerning the product’s structure and risks. Investors who suffered losses may be able to pursue recovery through FINRA arbitration or other legal remedies.
Did you suffer any losses because of investing in NexPoint Capital Inc. BDC because of your financial advisor or securities broker? You can contact Soreide Law Group at (888) 760-6552 or online and consult with a securities attorney regarding a potential recovery of your investment losses. Soreide Law Group has recovered losses for hundreds of individuals throughout the country. Also, our securities lawyers work on a contingency fee basis and advance all costs.
Soreide Law Group is investigating potential investor claims involving Infinity Financial Services after FINRA sanctioned the firm for supervisory failures involving deferred variable annuity exchanges and recommendations. Investors who incurred surrender charges or other losses in connection with variable annuity transactions recommended through Infinity should review the allegations that led to FINRA's disciplinary action against […]
Soreide Law Group is investigating potential investor claims involving losses in NextGenTech Investments LLC, a private fund managed by Sestante Capital LLC that purported to provide investors with economic exposure to shares of private companies, including Anduril Industries. Recent criminal proceedings involving Sestante Capital's manager have raised significant concerns regarding the offering, the representations made […]
Soreide Law Group is investigating potential investor claims involving losses sustained in Special Purpose Acquisition Companies (SPACs), particularly those sold during the 2020-2021 SPAC boom. During that period, hundreds of SPACs raised approximately $145 billion from investors and were promoted as an alternative path for private companies to enter the public markets. However, many companies […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com